- Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1]
- The risk of death was decreased by 59% in the 130 patients who completed VenR, versus BR, despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median overall survival (OS) was not reached for either treatment group[1]
- Sixty-eight percent of the 130 patients who completed the treatment course were free of disease progression and maintained OS benefit 24-months after being off therapy[1]
- Full results are being highlighted today in an oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition
PR Newswire
NORTH CHICAGO, Ill., Dec. 8, 2019
